0.3138
前日終値:
$0.328
開ける:
$0.3362
24時間の取引高:
2.29M
Relative Volume:
0.67
時価総額:
$33.10M
収益:
$147.75M
当期純損益:
$-284.23M
株価収益率:
-0.1071
EPS:
-2.93
ネットキャッシュフロー:
$-317.54M
1週間 パフォーマンス:
-0.38%
1か月 パフォーマンス:
-22.19%
6か月 パフォーマンス:
-22.79%
1年 パフォーマンス:
-86.65%
Fibrogen Inc Stock (FGEN) Company Profile
FGEN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
FGEN
Fibrogen Inc
|
0.3138 | 33.10M | 147.75M | -284.23M | -317.54M | -2.93 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-08-08 | ダウングレード | BofA Securities | Neutral → Underperform |
2023-06-26 | ダウングレード | BofA Securities | Buy → Neutral |
2023-06-26 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2023-06-26 | ダウングレード | Stifel | Buy → Hold |
2023-06-26 | ダウングレード | William Blair | Outperform → Mkt Perform |
2023-06-02 | アップグレード | Stifel | Hold → Buy |
2023-01-31 | アップグレード | William Blair | Mkt Perform → Outperform |
2023-01-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
2023-01-05 | アップグレード | BofA Securities | Neutral → Buy |
2021-09-22 | ダウングレード | Goldman | Neutral → Sell |
2021-08-20 | アップグレード | Raymond James | Underperform → Mkt Perform |
2021-07-16 | ダウングレード | BofA Securities | Buy → Neutral |
2021-07-16 | ダウングレード | Stifel | Buy → Hold |
2021-04-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2021-04-07 | ダウングレード | Mizuho | Buy → Neutral |
2021-03-31 | アップグレード | BofA Securities | Neutral → Buy |
2021-03-02 | ダウングレード | Jefferies | Buy → Hold |
2021-02-01 | 開始されました | H.C. Wainwright | Buy |
2020-10-26 | 開始されました | Raymond James | Underperform |
2020-07-10 | 再開されました | Stifel | Buy |
2020-05-01 | 開始されました | Cowen | Market Perform |
2020-04-27 | 開始されました | BofA/Merrill | Neutral |
2019-05-29 | 再開されました | Goldman | Neutral |
2019-05-10 | ダウングレード | William Blair | Outperform → Mkt Perform |
2019-04-12 | 開始されました | Piper Jaffray | Neutral |
2019-02-11 | 再開されました | Stifel | Buy |
2018-12-19 | アップグレード | Citigroup | Neutral → Buy |
2017-08-08 | 繰り返されました | Leerink Partners | Outperform |
2017-08-08 | 繰り返されました | Stifel | Buy |
2017-07-21 | ダウングレード | Goldman | Buy → Neutral |
2017-07-11 | 開始されました | Jefferies | Buy |
2016-02-11 | アップグレード | Credit Suisse | Neutral → Outperform |
2016-01-21 | 開始されました | Credit Suisse | Neutral |
2015-12-04 | 開始されました | Citigroup | Buy |
2015-09-23 | 開始されました | Lake Street | Hold |
2015-07-29 | 開始されました | Citigroup | Buy |
2015-07-20 | アップグレード | Goldman | Neutral → Buy |
2014-12-09 | 開始されました | Stifel | Buy |
すべてを表示
Fibrogen Inc (FGEN) 最新ニュース
FibroGen extends merger option deadline with Fortis By Investing.com - Investing.com South Africa
FibroGen extends merger option deadline with Fortis - Investing.com India
Morgan Stanley’s Adam Jonas Is Pounding the Table on This 1 ‘Unique’ Stock - The Globe and Mail
FibroGen reports promising FG-3246 study results for prostate cancer - Investing.com
FibroGen Announces Publication of Results from Phase 1 - GlobeNewswire
1 Top Cryptocurrency to Buy Before It Soars 14,623%, According to Michael Saylor - The Globe and Mail
Fibrogen CEO Wettig Thane buys $50,663 in common stock By Investing.com - Investing.com Australia
Fibrogen CEO Wettig Thane buys $50,663 in common stock - Investing.com India
Fibrogen director James Schoeneck buys $105,040 in stock By Investing.com - Investing.com Canada
In the Red? AstraZeneca Acquires FibroGen, Inc.’s China Subsidiary - Law Street Media
FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
FibroGen Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with ... - Yahoo Finance
FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with ... By GuruFocus - Investing.com Canada
FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with Strategic Initiatives - GuruFocus.com
FibroGen Announces Strategic Sale and Financial Outlook - TipRanks
FibroGen: Q4 Earnings Snapshot - mySA
Earnings call transcript: FibroGen reports Q4 2024 EPS beat, stock dips - Investing.com Canada
Earnings call transcript: FibroGen reports Q4 2024 EPS beat, stock dips By Investing.com - Investing.com South Africa
FibroGen Inc earnings beat by $0.35, revenue fell short of estimates - Investing.com Canada
FibroGen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FibroGen Inc Reports Q4 2024 Earnings: EPS Loss of $0.08 Beats E - GuruFocus.com
FIBROGEN INC SEC 10-K Report - TradingView
FibroGen, Inc. Announces Sale of FibroGen China to AstraZeneca for $160 Million and Updates on Clinical Trials - Nasdaq
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
FibroGen's Strategic $160M China Exit Extends Cash Runway to 2027 Amid Latest Earnings - StockTitan
FIBROGEN Earnings Preview: Recent $FGEN Insider Trading, Hedge Fund Activity, and More - Nasdaq
StockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN) - Defense World
Weekly CEO Buys Highlight: Camping World, FibroGen - GuruFocus.com
AstraZeneca’s $160 Million Acquisition of FibroGen China - Global Legal Chronicle
Ropes & Gray Advises FibroGen in $160 Million Sale of Fibrogen China to AstraZeneca - Ropes & Gray LLP
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
FibroGen, Inc. to Announce Q4 and Full Year 2024 Financial Results on March 17 - Nasdaq
When Will FibroGen Reveal Its 2024 Performance? Key Date for Investors Announced - StockTitan
FibroGen, Inc. to Host Earnings Call - ACCESS Newswire
FibroGen announces $30M "at the market" equity offering - Investing.com India
FibroGen announces $30M "at the market" equity offering By Investing.com - Investing.com South Africa
FibroGen Says Entered ATM Equity Offering Sales Agreement Relating To Sale From Time To Time Of Shares Of Common Stock - Marketscreener.com
Form 424B5 FIBROGEN INC - StreetInsider.com
Asia Deal Watch: AstraZeneca Buys FibroGen’s Chinese Subsidiary - Scrip
FibroGen Inc Announces Sale of China Subsidiary to AstraZeneca f - GuruFocus.com
Investor Network: FibroGen, Inc. to Host Earnings Call - ACCESS Newswire
FibroGen sells China biz to AstraZeneca for $160 M - BSA bureau
FibroGen (FGEN) Expected to Announce Quarterly Earnings on Monday - Defense World
FibroGen sells China unit to AstraZeneca for $160 million - MSN
AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal - MSN
Moody's Lifts AstraZeneca's Ratings, Revises Outlook to Stable -February 21, 2025 at 11:51 am EST - Marketscreener.com
FibroGen stock holds $10 target amid China unit sale By Investing.com - Investing.com Nigeria
Fibrogen Inc (FGEN) 財務データ
収益
当期純利益
現金流量
EPS
Fibrogen Inc (FGEN) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
Adib Deyaa | Chief Medical Officer |
Jun 12 '24 |
Buy |
1.17 |
22,123 |
25,884 |
82,123 |
大文字化:
|
ボリューム (24 時間):